生物活性 | |||
---|---|---|---|
描述 | 4-Phenylbutyric acid (4-PBA), known as an inhibitor of histone deacetylases (HDAC), effectively inhibits the growth of non-small cell lung cancer (NSCLC) cell lines at a concentration of 2 mM. When combined with ciglitizone, 4-Phenylbutyric acid further enhances the growth arrest of cancer cells[1]. Additionally, 4-Phenylbutyric acid, at concentrations ranging from 0 to 5 mM, dose-dependently inhibits African swine fever virus (ASFV) infection. 4-Phenylbutyric acid also disrupts ASFV-induced hypoacetylation of histone H3 at lysines 9 and 14 and inhibits late protein synthesis by the virus. The synergistic effect of 4-Phenylbutyric acid with enrofloxacin significantly eliminates ASFV replication[2]. The introduction of bafilomycin A1 leads to an increase in the accumulation of LC3II, a marker for autophagy, whereas 4-Phenylbutyric acid (4-PBA) substantially reduces this buildup. Lipopolysaccharide (LPS) lowers p62 levels, a process that is reversed by Benzenebutyric acid after 48 hours of LPS stimulation. Furthermore, while LPS increases the percentage of cells with acidotic vesicular organelles (AVOs) at 48 hours, 4-Phenylbutyric acid significantly lowers this percentage. Specifically, treatment with Benzenebutyric acid reduces the percentage of cells with AVOs from 61.6% to 53.1%, indicating that 4-Phenylbutyric acid inhibits LPS-induced autophagy[3]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
6.09mL 1.22mL 0.61mL |
30.45mL 6.09mL 3.05mL |
60.90mL 12.18mL 6.09mL |
参考文献 |
---|